Ondine Biomedical has the GF Score of 15, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Ondine Biomedical
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Ondine Biomedical GF Score Related Terms
OBIMF vs VRTX, REGN, ALNY: GF Score Comparison
For the Biotechnology subindustry, Ondine Biomedical's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ondine Biomedical GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ondine Biomedical's GF Score distribution charts can be found below:
* The bar in red indicates where Ondine Biomedical's GF Score falls into.
Ondine Biomedical (OBIMF) has a GF Score of 15 as of Jul. 12, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Ondine Biomedical and its competitors. This is 63% below median its historical median of 41.00. Over the past decade, Ondine Biomedical's GF Score has ranged from 20.00 to 56.00.
Is Ondine Biomedical's GF Score too high?
Ondine Biomedical's current GF Score of 15 is 63% below median its 10-year median of 41.00. Over the past 10 years, this metric has ranged from a low of 20.00 to a high of 56.00. Overall, Ondine Biomedical has a GF Score™ of 15/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's GF Score compare to VRTX and REGN?
Ondine Biomedical's GF Score of 15 can be compared against companies in the Biotechnology industry. Historically, Ondine Biomedical's own GF Score has ranged from 20.00 to 56.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Ondine Biomedical and its competitors. Ondine Biomedical's current GF Score is 15, which is 63% below median its own 10-year median of 41.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (OBIMF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $0.25 — trading 25% above its estimated fair value. The current GF Score is 15, which is 63% below median its 10-year median of 41.00. Ondine Biomedical's overall GF Score™ is 15/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Ondine Biomedical (OBIMF), the current GF Score is 15 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ondine Biomedical (OBIMF) Overvalued in 2026?
Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued.
The current stock price of $0.25 is trading 25% above its estimated GF Value™ of $0.20.
GuruFocus considers Ondine Biomedical to be Modestly Overvalued.
Key valuation signals for OBIMF:
GF Score: 15 (63% below median its 10-year median of 41.00)
GF Value™: $0.20 vs. price of $0.25 (25% above fair value)
No single metric tells the full story. See the OBIMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
15GF Score
Get the complete analysis for OBIMF
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBIMF has been successfully added to your 